Arete Wealth Advisors’s CorMedix CRMD Stock Holding History

Arete Wealth Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-5,000	Closed	-$24K	–	377
2018 Q3	$24K	Buy	+5,000	New	+$12.3K	0.01%	361

Other funds holding CRMD

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors Solana Beach, California $1.12B AUM 390.6% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Arete Wealth Advisors's CRMD Position: Q4 2018 in Review

Arete Wealth Advisors sold out of CorMedix (CRMD) in Q4 2018, closing a stake of 5,000 shares — an estimated $24K sold.

Arete Wealth Advisors first reported a position in CRMD in Q3 2018 and held it in 1 quarter. The position peaked at $24K in Q3 2018. 41 funds tracked by Wall St. Rank hold CRMD as of Q4 2018.

Arete Wealth Advisors reported no remaining CorMedix position as of Q4 2018 after selling out during the quarter.
Arete Wealth Advisors sold 5,000 CorMedix shares in Q4 2018, an estimated $24K.
Arete Wealth Advisors first reported a position in CorMedix in Q3 2018 and held it in 1 quarter.
Arete Wealth Advisors's CorMedix position peaked at $24K in Q3 2018.
41 funds tracked by Wall St. Rank held CorMedix as of Q4 2018.

Based on Arete Wealth Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.